

**Effective for dates of service on and after March 23, 2025**, the following updates will apply to the Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines. As part of the Carelon guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable health care services.

## Advanced Imaging/Radiology

### **Oncologic Imaging**

- NCCN alignments for Cancer Screening and tumor-specific indications (see Change Summary), largely addressing time intervals of screening or surveillance imaging.
- Added FDG PET allowances for Colorectal Cancer and Lung Cancer (Small Cell) accounting for nondiagnostic standard imaging.

### **Imaging of the Abdomen and Pelvis**

- Tumor or neoplasm – Added requirement for initial evaluation of testicular masses with US
- Endometriosis – Removed US requirement for follow-up of patients with established diagnosis
- Obstetric indications – Specified that fetal MRI is indicated in second or third trimester
- Diffuse liver disease – Removed criteria for LiverMultiScan as an alternative to MR elastography
- Abdominal and/or pelvic pain, undifferentiated – clarified language regarding initial imaging and lab evaluation

### **Imaging of the Chest**

- Added indication for dyspnea

For questions related to guidelines, please contact Carelon via email at [MedicalBenefitsManagement.guidelines@Carelon.com](mailto:MedicalBenefitsManagement.guidelines@Carelon.com). Additionally, you may access and download a copy of the current and upcoming guidelines [here](#).